Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
- DOI
- 10.1200/jco.23.02503
- Published
- 2024 Sep 20
- Container
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1200/jco.23.02503,
title = {Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.},
author = {Wirth LJ and Brose MS and Subbiah V and Worden F and Solomon B and Robinson B and Hadoux J and Tomasini P and Weiler D and Deschler-Baier B and Tan DSW and Maeda P and Lin Y and Singh R and Bayt T and Drilon A and Cassier PA},
year = {2024},
journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
doi = {10.1200/jco.23.02503},
url = {https://doi.org/10.1200/jco.23.02503}
}RIS
TY - JOUR TI - Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. AU - Wirth LJ AU - Brose MS AU - Subbiah V AU - Worden F AU - Solomon B AU - Robinson B AU - Hadoux J AU - Tomasini P AU - Weiler D AU - Deschler-Baier B AU - Tan DSW AU - Maeda P AU - Lin Y AU - Singh R AU - Bayt T AU - Drilon A AU - Cassier PA PY - 2024 JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology DO - 10.1200/jco.23.02503 UR - https://doi.org/10.1200/jco.23.02503 ER -
APA
LJ, W., MS, B., V, S., F, W., B, S., B, R., J, H., P, T., D, W., B, D., DSW, T., P, M., Y, L., R, S., T, B., A, D., & PA, C. (2024). Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco.23.02503
Source records
- pubmed · retrieved 2026-09-27T13:34:05.336Z